Meta-analysis of drug efficacy in adult vs pediatric trials of patients with PGTC seizures
Autor: | Douglas R. Nordli, Jinping Wang, Jacqueline A. French, Emilia Bagiella, Dinesh Kumar, Antonio Laurenza, Alexis Arzimanoglou |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adult
Male Topiramate Pediatrics medicine.medical_specialty Treatment response Adolescent MEDLINE Lamotrigine Article Efficacy 03 medical and health sciences 0302 clinical medicine Humans Medicine 030212 general & internal medicine Child business.industry Clinical trial Child Preschool Meta-analysis Anticonvulsants Female Epilepsy Tonic-Clonic Neurology (clinical) business 030217 neurology & neurosurgery medicine.drug Pediatric population |
Zdroj: | Neurology |
ISSN: | 1526-632X 0028-3878 |
Popis: | ObjectiveA meta-analysis of published studies was performed to determine whether the efficacy of antiseizure drugs in adults with primary generalized tonic-clonic seizures (PGTCS) is comparable with that in the pediatric population (2–12 years of age).MethodsElectronic searches were conducted in EMBASE, Medline, and the Cochrane Central Register of Controlled Trials for clinical trials of PGTCS in adults and children 2–12 years of age. Neurologists used standardized search and study evaluations to select eligible trials. Median percent reduction in seizure frequency from baseline and ≥50% responder rates were used to compare drug efficacy in adults and children.ResultsAmong 7 adjunctive-therapy PGTCS trials in adults and children (2–12 years of age) that met evaluation criteria, effect sizes were consistent between adults and children for lamotrigine and topiramate. The baseline-subtracted median percent seizure reduction in seizure frequency ranged from 50.0% to 79.7% in children and 57.0% to 64.0% in adults. The ≥50% responder rate was similar between children and adults in a topiramate study (50% in children compared with 58% in adults).ConclusionsThis meta-analysis supports the use of drug response from antiseizure drug clinical trials for PGTCS in adults to predict comparable treatment response in children 2–12 years of age with PGTCS. |
Databáze: | OpenAIRE |
Externí odkaz: |